A comparative study of 25 (OH) vitamin D serum levels in patients with multiple sclerosis and control group in Isfahan, Iran

International Journal of Preventive Medicine

Volumn 1, Issue 3, 2010, Pages 195-201

  Shaygannejad, Vahid ^a   Golabchi, Khodayar ^a   Haghighi, Sepehr ^a   Dehghan, Hamed ^a   Moshayedi, Amin ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

25(OH) vitamin D; Multiple sclerosis; Serum 25(OH) vitamin D level

Indexed keywords

25 HYDROXYVITAMIN D;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISABILITY; FEMALE; HIGH RISK POPULATION; HUMAN; IRAN; MALE; MULTIPLE SCLEROSIS; POPULATION BASED CASE CONTROL STUDY; REFERENCE VALUE; RISK ASSESSMENT; SUN EXPOSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 79952050175     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. th ed. Philadelphia: Churchill Livingstone; 2005. p. 982.
2. Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis - observations from Norway. Neuroepidemiology 2008; 30(3): 140-6.
3. Van Der Mei IAF, Ponsonby AL, Dwyer T, Blizzard CL, Taylor BVM, Kilpatrick T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. Journal of Neurology 2007; 254(5): 581-90.
4. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009; 256(9): 1468-79.
5. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 2009; 4(2): e4565.
6. Hayes CE, Donald AE. A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10. Med Hypotheses 2008; 71(1): 85-90.
7. Holmoy T. Vitamin D status modulates the immune response to Epstein Barr virus: Synergistic effect of risk factors in multiple sclerosis. Med Hypotheses 2008; 70(1): 66-9.
8. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194(1-2): 7-17.
9. Xu H, Soruri A, Gieseler RK, Peters JH. 1,25- Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol 1993; 38(6): 535-40.
10. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappa B down-regulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101(1): 252-62.
11. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alphahydroxylase in murine macrophages. Clin Exp Immunol 2000; 120(1): 139-46.
12. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86(2): 888-94.
13. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13(3): 100-5.
14. McGrath JJ, Feron FP, Burne TH, Mackay-Sim A, Eyles DW. Vitamin D3-implications for brain development. J Steroid Biochem Mol Biol 2004; 89-90(1-5): 557-60.
15. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995; 47(4-5): 425-48.
16. van der Mei I, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: casecontrol study. BMJ 2003; 327(7410): 316.
17. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62(1): 60-5.
18. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296(23): 2832-8.
19. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007; 254(4): 471-7.
20. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986; 21(2): 193-200.
21. Burton JM, Kimball S, Vieth R. A Phase I/II doseescalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis. Mult Scler 2008; 14 (Suppl 1): S34.
22. Wingerchuk DM, Lesaux J, Rice GPA, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 1294-6.
23. Souberbielle JC, Prié D, Courbebaisse M, Friedlander G, Houillier P, Maruani G et al. Actualité sur les effets de la vitamine D et l'évaluation du statut vitaminique D. Annales d'Endocrinologie 2008; 69(6):501-10.
24. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008; 87(4): 1087S-1091S.
25. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003; 89(5): 552-72.
26. Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. International Review of Neurobiology 2007; 79: 357-75.
27. Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 2006; 27(1): 39-44.
28. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979; 29(9 Pt 1): 1228-35.
29. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adultonset multiple sclerosis. Nat Rev Neurol 2010; 6(3): 156-66.
30. Acheson ED, BachrachA CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl 1960; 35(147): 132-47.
31. Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental? J Neurol Neurosurg Psychiatry 1990; 53(10): 903-5.
32. Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, English D, Holland JT, et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988; 111 (Pt 1): 1-25.
33. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7(5): 439-43.
34. Vukusic S, Van B, V, Gosselin S, Confavreux C. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry 2007; 78(7): 707-9.
35. van der Mei, I, Ponsonby AL, Engelsen O, Pasco JA, McGrath JJ, Eyles DW, et al. The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ Health Perspect 2007; 115(8): 1132-9.
36. Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand 1970; 46(4): 455-83.
37. Feskanich D, Willett WC, Colditz GA. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr 2003; 77(2): 504-11.
38. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 2004; 58(2): 142-4.
39. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005; 330(7483): 120.
40. Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007; 69(4): 381-8.
41. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008; 87(4): 1080S-1086S.
42. Prentice A. Vitamin D deficiency: a global perspective. Nutr Rev 2008; 66(10 Suppl 2): S153-S164.
43. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135(2): 317-22.
44. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25- hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77(1): 204-10.
45. Baumgartl HJ, Standl E, Schmidt-Gayk H, Kolb HJ, Janka HU, Ziegler AG. Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 1991; 16(3): 145-8.
46. Brehm JM, Celedon JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 2009; 179(9): 765-71.
47. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003; 100(22): 12877-82.